Post-marketing surveillance indicates a possible link between omeprazole consumption and changes in cognitive abilities; however, existing observational studies have yielded conflicting outcomes. This highlights the lack of consensus and underscores the imperative for further systematic investigation to elucidate this relationship.
Objective
This investigation thoroughly examined the connection between omeprazole administration and reported memory issues, with the goal of supplying empirical support for evaluating the medication's safety profile and determining its risk-benefit balance in clinical practice.
Methods
We employed a range of analytical approaches, including descriptive statistics, multivariable logistic regression, and receiver operating characteristic curve analysis, to systematically evaluate the association between omeprazole use and memory function. Network pharmacology further characterized omeprazole's molecular targets and pathways linked to memory deficits.
Results
In the National Health and Nutrition Examination Survey (NHANES) analysis, it revealed a significant positive association between omeprazole consumption and memory impairment (OR [95% CI] = 3.51 [1.87, 6.59]). Through network pharmacology, 342 core targets related to Alzheimer's disease were identified. The top 10 potential binding targets of omeprazole—UBA52, RPL23, RPS18, RPL4, RPL15, RPL11, RPS6, EGFR, RPL13, and RPS20—exhibited strong binding affinities. The enrichment analysis implies a role for omeprazole in causing memory issues, possibly by affecting processes like carboxylic acid metabolism and membrane transportation.
Conclusions
Mounting research from both large-scale population studies and drug safety surveillance reports paints a clear picture: regular omeprazole consumption appears to hike the chances of experiencing cognitive hiccups related to memory function.
KhanSBarveKHKumarMS. Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer’s disease. Curr Neuropharmacol2020; 18: 1106–1125.
2.
Raise-AbdullahiPRaeis-AbdollahiEMeamarM, et al.Effects of coffee on cognitive function. Prog Brain Res2024; 288: 133–166.
3.
ZameerSAkhtarMVohoraD. Behavioral experimental paradigms for the evaluation of drug’s influence on cognitive functions: interpretation of associative, spatial/nonspatial and working memory. CNS Neurol Disord Drug Targets2019; 18: 185–204.
4.
LökNBademliKSelçuk-TosunA. The effect of reminiscence therapy on cognitive functions, depression, and quality of life in Alzheimer patients: randomized controlled trial. Int J Geriatr Psychiatry2019; 34: 47–53.
5.
OosterhuisBJonkmanJH. Omeprazole: pharmacology, pharmacokinetics and interactions. Digestion1989; 44: 9–17.
6.
RotmanSRBishopTF. Proton pump inhibitor use in the U.S. Ambulatory setting, 2002–2009. PLoS One2013; 8: e56060.
7.
DipasqualeVCicalaGLaganàF, et al.Spontaneous reporting of adverse reactions related to proton pump inhibitors. Dig Liver Dis2023; 55: 595–600.
8.
TargownikLELixLMMetgeCJ, et al.Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ2008; 179: 319–326.
9.
KuoH-YLiangC-STsaiS-J, et al.Dose-dependent proton pump inhibitor exposure and risk of type 2 diabetes: a nationwide nested case-control study. Int J Environ Res Public Health2022; 19: 8739.
10.
PerryTW. Abrupt-onset, profound erectile dysfunction in a healthy young man after initiating over-the-counter omeprazole: a case report. J Med Case Rep2021; 15: 360.
11.
HaenischBvon HoltKWieseB, et al.Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci2015; 265: 419–428.
12.
Nevado-HolgadoAJKimC-HWinchesterL, et al.Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK biobank. BMJ Open2016; 6: e012177.
13.
WuBXiaoMWuF, et al.Signal of dementia with proton pump inhibitor after minimizing competition bias: an updated disproportionality analysis. Expert Opin Drug Saf2025; 24: 969–976.
14.
TaipaleHTolppanenA-MTiihonenM, et al.No association between proton pump inhibitor use and risk of Alzheimer’s disease. Am J Gastroenterol2017; 112: 1802–1808.
15.
HussainSSinghAZameerS, et al.No association between proton pump inhibitor use and risk of dementia: evidence from a meta-analysis. J Gastroenterol Hepatol2020; 35: 19–28.
16.
XuJWangFZangC, et al.Comparing the effects of four common drug classes on the progression of mild cognitive impairment to dementia using electronic health records. Sci Rep2023; 13: 8102.
17.
ZhangHHuangHZhaoP. Correlation of atorvastatin with subjective memory deficits: a study from the NHANES and FAERS databases. Front Neurol2025; 16: 1526959.
18.
ZhangHOuHZhaoP, et al.Association between finasteride with subjective memory deficits: a study from the NHANES and FAERS databases. Front Neurol2025; 16: 1616851.
19.
NahmFS. Receiver operating characteristic curve: overview and practical use for clinicians. Korean J Anesthesiol2022; 75: 25–36.
20.
DainaAMichielinOZoeteV. Swisstargetprediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res2019; 47: W357–W364.
21.
StelzerGRosenNPlaschkesI, et al.The GeneCards suite: from gene data mining to disease genome sequence analyses. Curr Protoc Bioinformatics2016; 54: 1.30.1–1.30.33.
22.
SzklarczykDKirschRKoutrouliM, et al.The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res2023; 51: D638–D646.
23.
GommWvon HoltKThoméF, et al.Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol2016; 73: 410–416.
24.
AhnNWawroNBaumeisterS-E, et al.Time-varying use of proton pump inhibitors and cognitive impairment and dementia: a real-world analysis from Germany. Drugs Aging2023; 40: 653–663.
25.
WeissAGingold-BelferRBoltinD, et al.Chronic omeprazole use in the elderly is associated with decreased risk of dementia and cognitive decline. Dig Liver Dis2022; 54: 622–628.
26.
Azargoonjahromi A and Alzheimer’s Disease Neuroimaging Initiative. Serotonin enhances neurogenesis biomarkers, hippocampal volumes, and cognitive functions in Alzheimer’s disease. Mol Brain2024; 17: 93.
27.
AliSBMahmoodKSaeedR, et al.Elevated anxiety, hypoactivity, memory deficits, decreases of brain serotonin and 5-HT-1A receptors expression in rats treated with omeprazole. Toxicol Res2021; 37: 237–248.
28.
SamadNManzoorNIrfanA, et al.Gallic acid alleviates omeprazole-induced depressive behavior and memory impairment. Naunyn Schmiedebergs Arch Pharmacol2025; 398: 10317–10335.
29.
HaamJYakelJL. Cholinergic modulation of the hippocampal region and memory function. J Neurochem2017; 142: 111–121.
30.
KumarRKumarANordbergA, et al.Proton pump inhibitors act with unprecedented potencies as inhibitors of the acetylcholine biosynthesizing enzyme-A plausible missing link for their association with incidence of dementia. Alzheimers Dement2020; 16: 1031–1042.
31.
KhareVKourSAlamN, et al.Synthesis, characterization and mechanistic-insight into the anti-proliferative potential of PLGA-gemcitabine conjugate. Int J Pharm2014; 470: 51–62.
32.
FrankfurtMLuineV. The evolving role of dendritic spines and memory: interaction(s) with estradiol. Horm Behav2015; 74: 28–36.
33.
ThongonNChamniansawatS. Hippocampal synaptic dysfunction and spatial memory impairment in omeprazole-treated rats. Metab Brain Dis2022; 37: 2871–2881.
34.
CoelhoDMNCosta JúniorDCda SilvaDMA, et al.Long-term administration of omeprazole in mice: a study of behavior, inflammatory, and oxidative stress alterations with focus on central nervous system. Naunyn Schmiedebergs Arch Pharmacol2024; 397: 6165–6175.
35.
RahmanMMCallaghanCKKerskensCM, et al.Early hippocampal volume loss as a marker of eventual memory deficits caused by repeated stress. Sci Rep2016; 6: 29127.
36.
HardyJSelkoeDJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science2002; 297: 353–356.
MajumdarACruzDAsamoahN, et al.Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils. Mol Biol Cell2007; 18: 1490–1496.
SongQMengBXuH, et al.The emerging roles of vacuolar-type ATPase-dependent lysosomal acidification in neurodegenerative diseases. Transl Neurodegener2020; 9: 17.
41.
LauerAAGrimmHSApelB, et al.Mechanistic link between vitamin B12 and Alzheimer’s disease. Biomolecules2022; 12: 129.
42.
LamJRSchneiderJLZhaoW, et al.Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA2013; 310: 2435–2442.
43.
TiwariSSinghAGuptaP, et al.UBA52 Attunes VDAC1-mediated mitochondrial dysfunction and dopaminergic neuronal death. ACS Chem Neurosci2023; 14: 839–850.
44.
SuzukiMTezukaKHandaT, et al.Upregulation of ribosome complexes at the blood-brain barrier in Alzheimer’s disease patients. J Cereb Blood Flow Metab2022; 42: 2134–2150.
45.
DecourtCSchaefferJBlotB, et al.The RSK2-RPS6 axis promotes axonal regeneration in the peripheral and central nervous systems. PLoS Biol2023; 21: e3002044.
46.
HashiokaSKlegerisAMcGeerPL. Proton pump inhibitors reduce interferon-γ-induced neurotoxicity and STAT3 phosphorylation of human astrocytes. Glia2011; 59: 833–840.
47.
PinheiroLCOliveira-PaulaGHPortellaRL, et al.Omeprazole impairs vascular redox biology and causes xanthine oxidoreductase-mediated endothelial dysfunction. Redox Biol2016; 9: 134–143.
